Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company focused on RNA editing for rare and prevalent diseases, has announced significant changes to its Board of Directors. Dr. Katharine Knobil, an industry veteran with over 25 years of experience, has been appointed as an Independent Director. Dr. Knobil brings extensive expertise in clinical development and regulatory affairs, having held key positions at Agilent Technologies, Kaleido Biosciences, and GlaxoSmithKline.
Simultaneously, David Lucchino has stepped down from the Board. Dr. Ram Aiyar, CEO and President of Korro, expressed enthusiasm about Dr. Knobil's appointment, highlighting her valuable experience as the company advances its innovative pipeline. Dr. Knobil shared her excitement about joining Korro and contributing to the advancement of RNA editing technology.
Korro Bio, Inc. (Nasdaq: KRRO), un'azienda biofarmaceutica focalizzata sull'editing dell'RNA per malattie rare e diffuse, ha annunciato importanti cambiamenti nel suo Consiglio di Amministrazione. Dr. Katharine Knobil, veterana del settore con oltre 25 anni di esperienza, è stata nominata Direttore Indipendente. La Dr. Knobil porta con sé una vasta esperienza nello sviluppo clinico e negli affari normativi, avendo ricoperto ruoli chiave presso Agilent Technologies, Kaleido Biosciences e GlaxoSmithKline.
Contemporaneamente, David Lucchino si è dimesso dal Consiglio. Il Dr. Ram Aiyar, CEO e Presidente di Korro, ha espresso entusiasmo per la nomina della Dr. Knobil, sottolineando la sua preziosa esperienza mentre l'azienda avanza nel suo innovativo pipeline. La Dr. Knobil ha condiviso il suo entusiasmo per entrare a far parte di Korro e contribuire all'avanzamento della tecnologia di editing dell'RNA.
Korro Bio, Inc. (Nasdaq: KRRO), una empresa biofarmacéutica centrada en la edición de ARN para enfermedades raras y prevalentes, ha anunciado cambios significativos en su Junta Directiva. Dr. Katharine Knobil, una veterana de la industria con más de 25 años de experiencia, ha sido nombrada Directora Independiente. La Dra. Knobil aporta una amplia experiencia en desarrollo clínico y asuntos regulatorios, habiendo ocupado posiciones clave en Agilent Technologies, Kaleido Biosciences y GlaxoSmithKline.
Al mismo tiempo, David Lucchino ha renunciado a la Junta. El Dr. Ram Aiyar, CEO y Presidente de Korro, expresó su entusiasmo por el nombramiento de la Dra. Knobil, destacando su valiosa experiencia mientras la empresa avanza en su innovador pipeline. La Dra. Knobil compartió su entusiasmo por unirse a Korro y contribuir al avance de la tecnología de edición de ARN.
Korro Bio, Inc. (Nasdaq: KRRO)는 희귀 및 일반 질환을 위한 RNA 편집에 집중하는 생명공학 회사로, 이사회를 대폭 변경했다고 발표했습니다. Dr. Katharine Knobil는 25년 이상의 경력을 가진 업계 전문가로 독립 이사로 임명되었습니다. Knobil 박사는 Agilent Technologies, Kaleido Biosciences 및 GlaxoSmithKline에서 핵심 직책을 역임하며 임상 개발 및 규제 업무에 대한 폭넓은 전문성을 제공합니다.
동시에 David Lucchino가 이사회에서 물러났습니다. Korro의 CEO이자 사장인 Ram Aiyar 박사는 Knobil 박사의 임명에 대해 열정을 표명하며 회사가 혁신적인 파이프라인을 발전시키는 데 그녀의 귀중한 경험이 중요하다고 강조했습니다. Knobil 박사는 Korro에 합류하고 RNA 편집 기술 발전에 기여하게 되어 기쁘다고 전했습니다.
Korro Bio, Inc. (Nasdaq: KRRO), une entreprise biopharmaceutique axée sur l'édition de l'ARN pour des maladies rares et répandues, a annoncé des changements significatifs au sein de son Conseil d'Administration. Dr. Katharine Knobil, une vétérane de l'industrie avec plus de 25 ans d'expérience, a été nommée Directrice Indépendante. Dr. Knobil apporte une vaste expertise dans le développement clinique et les affaires réglementaires, ayant occupé des postes clés chez Agilent Technologies, Kaleido Biosciences et GlaxoSmithKline.
Simultanément, David Lucchino a démissionné du Conseil. Dr. Ram Aiyar, PDG et Président de Korro, a exprimé son enthousiasme à propos de la nomination de Dr. Knobil, soulignant son expérience précieuse alors que l'entreprise progresse dans son pipeline innovant. Dr. Knobil a partagé son enthousiasme à rejoindre Korro et à contribuer à l'avancement de la technologie d'édition de l'ARN.
Korro Bio, Inc. (Nasdaq: KRRO), ein biopharmazeutisches Unternehmen, das sich auf RNA-Editing für seltene und verbreitete Krankheiten spezialisiert hat, hat bedeutende Änderungen in seinem Verwaltungsrat bekannt gegeben. Dr. Katharine Knobil, eine Branchenveteranin mit über 25 Jahren Erfahrung, wurde zur Unabhängigen Direktorin ernannt. Dr. Knobil bringt umfassende Expertise in der klinischen Entwicklung und den regulatorischen Angelegenheiten mit, nachdem sie Schlüsselpositionen bei Agilent Technologies, Kaleido Biosciences und GlaxoSmithKline innehatte.
Gleichzeitig hat David Lucchino seinen Rücktritt aus dem Vorstand bekannt gegeben. Dr. Ram Aiyar, CEO und Präsident von Korro, äußerte sich begeistert über die Ernennung von Dr. Knobil und hob ihre wertvolle Erfahrung hervor, während das Unternehmen sein innovatives Pipeline vorantreibt. Dr. Knobil teilte ihre Begeisterung über ihren Eintritt bei Korro und ihren Beitrag zur Weiterentwicklung der RNA-Editing-Technologie.
- Appointment of Dr. Katharine Knobil, an industry veteran with 25+ years of experience, as Independent Director
- Dr. Knobil brings expertise in clinical development and regulatory affairs
- Dr. Knobil's experience includes leadership roles at major pharmaceutical companies
- Resignation of David Lucchino from the Board of Directors
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board.
Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage development to regulatory approval and commercialization. She most recently served as Chief Medical Officer at Agilent Technologies, where she established an industry-leading medical affairs organization and was responsible for integrating the voice of patients into business and clinical development strategy and decision-making. Previously, she was Chief Medical Officer and Head of Research and Development at Kaleido Biosciences. Before that, Dr. Knobil spent more than 20 years at GlaxoSmithKline (GSK) in roles of increasing responsibility, most recently serving as Chief Medical Officer. Dr. Knobil is currently a member of the Board of Directors at Nimbus Therapeutics, Marker Therapeutics (NASDAQ: MRKR) and Pliant Therapeutics (NASDAQ: PLRX). Dr. Knobil is a recognized leader in the field, having authored numerous publications and presented at major industry conferences. She received an M.D. from the University of Texas Southwestern Medical School and completed her subsequent fellowship in Pulmonary Medicine and Critical Care Medicine at Johns Hopkins University.
“We are thrilled to welcome Kate to our Board. Her extensive clinical expertise and deep understanding of the regulatory landscape will be invaluable as we continue to advance our pipeline of innovative programs. Kate's leadership will help guide our mission to address unmet medical needs and strengthen Korro's commitment to leveraging top-tier clinical and regulatory expertise,” said Dr. Ram Aiyar, CEO and President of Korro.
“I am honored to join Korro’s Board at such an exciting time for the company,” said Dr. Knobil. “I look forward to working with the Board and management team to help advance the company's mission and make a meaningful impact on patients' lives. The opportunity to be part of a company at the forefront of RNA editing technology is particularly exciting to me. I believe RNA editing has the potential to revolutionize the treatment of a wide range of diseases, and I am eager to contribute to the advancement of these groundbreaking programs.”
“On behalf of the Board and the management team, I would like to thank David for his service and commitment to Korro’s mission and vision,” added Dr. Aiyar. “David provided significant contributions and guidance during our transition from a private company to our public listing on Nasdaq last year. We wish him the best on his future endeavors.”
Reflecting on his tenure, Mr. Lucchino stated, “It has been an honor to serve on the Board of Korro and to contribute to its remarkable journey. I am proud of what we have accomplished together and am confident the company is in excellent hands with the leadership team and the addition of Dr. Knobil to the Board. I look forward to seeing the company's continued success.”
About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro Contact Information
Investors
IR@korrobio.com
Media
Glenn Silver
FINN Partners
Glenn.silver@finnpartners.com
FAQ
Who is the new Independent Director appointed to Korro Bio's (KRRO) Board?
What is Dr. Katharine Knobil's background and experience relevant to Korro Bio (KRRO)?
Who has resigned from Korro Bio's (KRRO) Board of Directors?
What is Korro Bio's (KRRO) focus in the biopharmaceutical industry?
